South & Central America ELISA Diagnostics Tests Market Forecast to 2030 - Regional Analysis - by Adoption, Test Type, Application, and End User

The South & Central America ELISA diagnostics tests market was valued at US$ 87.77 million in 2022 and is expected to reach US$ 129.69 million by 2030; it is estimated to grow at a CAGR of 5.0% from 2022 to 2030.

Innovative Product Launches Bolster South & Central America ELISA Diagnostics Tests Market

ELISA is one of the most popular immunoassay tests owing to its various advantages such as flexibility, sensitivity, and easy-to-use features. Also, low cost of ELISA test kit and multifaceted applicability associated with high-throughput testing make it an ideal solution for various research and IVD requirements. With low-cost applicability, product innovations in the test kits enhance the demand for human and animal research. Also, manufacturers focus on developing ELISA test kits with in-house facilities. Innovative Research company sells a wide range of ELISA kits with selectivity to a broad range in identifying coagulants, species, and antibodies. "Human Factor IX Kit" is one such example manufactured by Innovative Research. The human coagulation Factor IX antigen assay is intended for the quantitative determination of total Factor IX antigen in human plasma. The kit is recommended to use only for research purposes, and reagents can be utilized for up to 96 clinical tests. Additionally, innovative product launches for ELISA tests by the manufacturers amid the COVID-19 pandemic accelerate the adoption of ELISA testing among humans. In December 2022, Pictor Limited announced a new product launch of the "PictArray SARS-CoV-2 Antibody Test," which has demonstrated real clinical utility intended for patients and doctors. The new product detects the infection associated with the COVID-19 virus, and the clinical results produced assist the patients and doctors in treating and managing SARS-CoV-2 infection. Launches of innovative ELISA test kits by manufacturers are expected to provide effective clinical results for diagnosing varied infections associated with different types of species with low cost and multifaceted applications. Thus, innovative product launches would provide lucrative opportunities for manufacturers in the long run.

South & Central America ELISA Diagnostics Tests Market Overview

In Brazil, amid the COVID-19 pandemic, several top manufacturers launched innovative ELISA-based products to diagnose COVID-19 with lower chances by avoiding false negative results. CT Vacinas, a center formed by researchers at the Federal University of Minas Gerais (UFMG) and the Oswaldo Cruz Foundation (Fiocruz), is one such example. Also, the ELISA-based COVID-19 diagnostic kit provided by CT Vacinas is comparably a cheaper product than other kits such as RT-PCR in Sau Paulo.

Further, the American Association for the Advancement of Science (AAAS) 2023 report revealed that Brazilian startup "Biolinker" in Sau Paulo developed a low-cost, high-performance COVID-19 diagnostic test kit. Amid the pandemic, within a few months, the company planned to complete the development of a standardized kit for the detection of IgG circulating antibodies in blood serum produced for SARS-CoV-2 variants. The method used for manufacturing the standardized kit was ELISA. The kit produced by ELISA platform was affordable and quick test that can be used anywhere for epidemiological screening purposes for COVID-19 patients. Therefore, aforementioned factors are responsible for the ELISA diagnostic test market growth in Brazil.

South & Central America ELISA Diagnostics Tests Market Segmentation

The South & Central America ELISA diagnostics tests market is segmented based on adoption, test type, application, end user, and country. Based on adoption, the South & Central America ELISA diagnostics tests market is bifurcated into human and veterinary. The human segment held a larger market share in 2022.

In terms of test type, the South & Central America ELISA diagnostics tests market is segmented into sandwich ELISA, indirect ELISA, competitive ELISA, and multiple & portable ELISA. The indirect ELISA segment held the largest market share in 2022.

Based on application, the South & Central America ELISA diagnostics tests market is segmented into autoimmune diseases, infectious diseases, cancer diagnosis, protein quantification, and others. The infectious diseases segment held the largest market share in 2022.

By end user, the South & Central America ELISA diagnostics tests market is segmented into hospitals & diagnostic centers, pharmaceutical & biotechnology companies, veterinary hospitals & diagnostic laboratories, and others. The hospitals & diagnostic centers segment held the largest market share in 2022.

Based on country, the South & Central America ELISA diagnostics tests market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America ELISA diagnostics tests market share in 2022.

Bio-Rad Laboratories Inc., Idexx Laboratories Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corp., DiaSorin SpA, and Elabscience Biotechnology Inc. are some of the leading companies operating in the South & Central America ELISA diagnostics tests market.